| Fri 1 Jun 2012, 7:05 | | AIP - Adcock Ingram Holdings Limited - Appointments to the Board of Directors |
|
AIP
AIP
AIP - Adcock Ingram Holdings Limited - Appointments to the Board of Directors
Adcock Ingram Holdings Limited
(Registration number 2007/016236/06)
(Incorporated in the Republic of South Africa)
Share code: AIP
ISIN: ZAE000123436
("Adcock Ingram" or "the Company")
APPOINTMENTS TO THE BOARD OF DIRECTORS
In accordance with paragraph 3.59 of the Listings Requirements of the JSE
Limited, shareholders are advised that Professor Mattias Haus has been appointed
as a Non-Executive Director of Adcock with effect from 01 June 2012. His work
experience is summarised below:
Professor Haus
After graduating from the University of Cape Town in 1974, Professor Haus spent
seven years in private general practice and five years in Paediatrics at the Red
Cross War Memorial Children`s Hospital, during which time he obtained a research
doctorate (M.D.) from the University of Cape Town (UCT).
He holds two post-graduate Diplomas from the Colleges of Medicine of South
Africa in Paediatrics, and Obstetrics and Gynaecology, and is a Fellow of both
the Royal College of Physicians (UK) and the College`s of Medicine of South
Africa. Professor Haus has been awarded the Claude Harris Leon Medal of the
Colleges, for which body he was previously a College and Senate Member, Examiner
and Editor of Transactions, the Colleges` Journal. He was awarded the Financial
Mail Rare Achievers Award for Science and Technology in 1989, and also awarded
the 2003 FARMOVS prize for his contribution to Medical Research in South Africa
from the South African Academy of Science and Technology, and the 2005 National
Wits University Award for his contribution to Cancer research and patient care.
His academic research has been widely published and he has managed collaborative
research projects with the National Institutes of Health (NIH) (Atlanta), the
University of Cape Town, the British Medical Research Council`s Epidemiology
Unit and the Karolinska Institute at the University of Stockholm. He has a
special interest in the epidemiology and immunology of the Allergic Response,
and has published and lectured widely both nationally and internationally on
academic, pharmaceutical and philosophic related topics. Over the past 25
years, he has directed clinical pharmaceutical research in South Africa, the
Asia Pacific region and in Latin America with more than 100 New Chemical
Entities. In 2004, he was seconded to the People`s Republic of China as Vice
President for Research and Development for AstraZeneca, China.
Apart from his academic career, Professor Haus has been active in many areas of
Commerce, Industry and the Financial Services Sector. He was a non-executive
Director of the Professional Provident Society for ten years, Deputy Chairman of
the PPS Holding Company, and Chairman of both the PPS Holding Company and PPS
Insurance Company.
Professor Haus is past Chairman of the Allergy Society of South Africa, a
Director and Trustee of various other companies, was appointed Adjunct Professor
(Faculty of Health Sciences, UCT) in 2000, and served on a World Health
Organisation Task Force compiling guidelines for the Prevention of Asthma and
Allergic Diseases. He has worked closely with the Singapore based INSEAD
Business School on the steering committee of an Asian initiative to introduce
best business practice in medical Research and Development to the AstraZeneca
group of companies in the Region, and has lectured at INSEAD on consumer
branding, and at Cambridge University on Clinical Immunology.
In 2011, he took mandatory retirement as Executive Director responsible for
Clinical, Medical and Regulatory Affairs for AstraZeneca (South Africa),
retaining his professorial duties at the UCT. Currently, he is a Trustee of the
Colleges of Medicine of South Africa and Chairman of the Moments in Time
Charitable Trust. He is a Senior Consultant at Gateways Consulting, and
practices clinical medicine in allergology with the Netcare group. He is a
Board Member of the Lonehill Residents Association, and was appointed Editor of
the Journal "Current Allergy and Clinical Immunology" in 2012. He is a
freelance Journalist for the Media 24 Group.
The Board congratulates Professor Haus on his appointment and wishes him well in
his roles.
Midrand
1 June 2012
Sponsor: Deutsche Securities (SA) (Proprietary) Limited
Date: 01/06/2012 07:05:12 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
